Systemic Lupus Erythematosus and COVID-19.

IF 5.7 2区医学 Q1 RHEUMATOLOGY Current Rheumatology Reports Pub Date : 2023-10-01 Epub Date: 2023-07-21 DOI:10.1007/s11926-023-01110-z

Maria Pappa, Alexandros Panagiotopoulos, Konstantinos Thomas, Antonis Fanouriakis

{"title":"Systemic Lupus Erythematosus and COVID-19.","authors":"Maria Pappa, Alexandros Panagiotopoulos, Konstantinos Thomas, Antonis Fanouriakis","doi":"10.1007/s11926-023-01110-z","DOIUrl":null,"url":null,"abstract":"Purpose of review: To describe the current state of knowledge regarding COVID-19 in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 vaccination uptake, immunogenicity and safety, and (ii) outcomes of COVID-19 in patients with SLE and pertinent risk factors for adverse sequelae.Recent findings: Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications.","PeriodicalId":10761,"journal":{"name":"Current Rheumatology Reports","volume":"25 10","pages":"192-203"},"PeriodicalIF":5.7000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504107/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Rheumatology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11926-023-01110-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To describe the current state of knowledge regarding COVID-19 in patients with systemic lupus erythematosus (SLE). We focus on (i) SARS-CoV-2 vaccination uptake, immunogenicity and safety, and (ii) outcomes of COVID-19 in patients with SLE and pertinent risk factors for adverse sequelae.

Recent findings: Notwithstanding the potential concern of patients about possible post-vaccination side-effects, the safety of anti-SARS-CoV-2 vaccines in patients with SLE has been undisputedly confirmed in numerous studies. Humoral immunogenicity is generally attained in SLE, although affected by the use of background immunosuppressive drugs, especially rituximab. The latter has also clearly been implicated with adverse COVID-19 outcomes in SLE, including need for hospitalization, mechanical ventilation and death. Although the wide adoption of vaccination has significantly improved COVID-19 outcomes, patients with SLE continue to pose challenges during the pandemic, mainly owing to administered immunosuppressive medications.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

系统性红斑狼疮与新冠肺炎。

综述目的：描述系统性红斑狼疮（SLE）患者对新冠肺炎的认识现状。我们重点关注（i）SARS-CoV-2疫苗接种率、免疫原性和安全性，以及（ii）SLE患者的新冠肺炎结果和不良后遗症的相关风险因素。最近的发现：尽管患者可能担心疫苗接种后可能出现的副作用，但抗严重急性呼吸系统综合征冠状病毒2型疫苗在SLE患者中的安全性已在大量研究中得到证实。SLE通常会获得体液免疫原性，尽管会受到背景免疫抑制药物的影响，尤其是利妥昔单抗。后者也明显与SLE的新冠肺炎不良后果有关，包括需要住院、机械通气和死亡。尽管疫苗接种的广泛采用显著改善了新冠肺炎的结果，但SLE患者在大流行期间仍然面临挑战，主要是由于服用了免疫抑制药物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Rheumatology Reports RHEUMATOLOGY-

CiteScore

11.20

自引率

0.00%

发文量

期刊介绍： This journal aims to review the most important, recently published research in the field of rheumatology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care and prevention of rheumatologic conditions. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas such as the many forms of arthritis, osteoporosis and metabolic bone disease, and systemic lupus erythematosus. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also occasionally provided.